A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

被引：13
|
作者：
Slomovitz, B. M.
Lu, K. H.
Johnston, T.
Munsell, M.
Ramondetta, L. M.
Broaddus, R. R.
Coleman, R. L.
Walker, C.
Gershenson, D. M.
Burke, T. W.
Wolf, J.
机构：
[1] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5502
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5502
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
    Parikh, Sameer A.
    Kantarjian, Hagop M.
    Richie, Mary Ann
    Cortes, Jorge E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2010, 51 (02) : 269 - 274
  • [2] A Phase 2 Study of the Oral Mammalian Target of Rapamycin Inhibitor, Everolimus, in Patients With Recurrent Endometrial Carcinoma
    Slomovitz, Brian M.
    Lu, Karen H.
    Johnston, Taren
    Coleman, Robert L.
    Munsell, Mark
    Broaddus, Russell R.
    Walker, Cheryl
    Ramondetta, Lois M.
    Burke, Thomas W.
    Gershenson, David M.
    Wolf, Judith
    CANCER, 2010, 116 (23) : 5415 - 5419
  • [3] Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    Yee, Karen W. L.
    Zeng, Zhihong
    Konopleva, Marina
    Verstovsek, Srdan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Thomas, Deborah
    Wierda, William
    Apostolidou, Efrosyni
    Albitar, Maher
    O'Brien, Susan
    Andreeff, Michael
    Giles, Francis J.
    CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5165 - 5173
  • [4] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Maruyama, Dai
    Uchida, Toshiki
    Uike, Naokuni
    Choi, Ilseung
    Ishizawa, Kenichi
    Itoh, Kuniaki
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Shimada, Naomi
    Kobayashi, Ken
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 563 - 570
  • [6] Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
    Kensei Tobinai
    Michinori Ogura
    Dai Maruyama
    Toshiki Uchida
    Naokuni Uike
    Ilseung Choi
    Kenichi Ishizawa
    Kuniaki Itoh
    Kiyoshi Ando
    Masafumi Taniwaki
    Naomi Shimada
    Ken Kobayashi
    International Journal of Hematology, 2010, 92 : 563 - 570
  • [7] The mTOR (mammalian target of rapamycin) inhibitor RAD001 (Everolimus) is safe and reduces proliferation in postmenopausal women with breast cancer
    Macaskill, E. J.
    Bartlett, J. M. S.
    Renshaw, L.
    Faratian, D.
    White, S.
    Campbell, F. M.
    Young, O.
    Stumm, M.
    Thomas, J.
    Barber, M. D.
    Dixon, J. M.
    EJC SUPPLEMENTS, 2007, 5 (03): : 30 - 30
  • [8] A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC)
    Chan, J. S.
    Vuky, J.
    Besaw, L. A.
    Beer, T. M.
    Ryan, C. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Thomas Decker
    Michael Sandherr
    Katharina Goetze
    Madlen Oelsner
    Ingo Ringshausen
    Christian Peschel
    Annals of Hematology, 2009, 88 : 221 - 227
  • [10] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Decker, Thomas
    Sandherr, Michael
    Goetze, Katharina
    Oelsner, Madlen
    Ringshausen, Ingo
    Peschel, Christian
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 221 - 227
12345